C. difficile infections generate an annual economic burden of more than $1 billion. Traditional first line treatment includes antibiotics. Researchers found FMT to be more cost-effective than metronidazole and fidaxomicin.
The researchers concluded that C. difficile infection treatment guidelines should consider recommending use of FMT at an earlier time.
More Articles on Gastroenterology:
6 Statistics on Colorectal Cancer Diagnosis & Mortality
2014 Outlook: 7 Issues for Gastroenterologists to Focus on This Year
5 Things to Know About Advances in Oral Treatment for Hepatitis C
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
